People of Pathology Podcast
Episodes
Episode 185: Jacob Guggenheim – Augmenting Grossing With AI: The Sentinel From Vistapath
Jacob Guggenheim is head of engineering at Vistapath. Their innovative Sentinel is bringing AI to specimen grossing.
-
Jacob’s background in bioengineering and robotics led him to join Vistapath
-
Vistapath’s mission is to improve the efficiency and accuracy of the histology process, inspired by a real-world incident
-
The Sentinel is designed to augment human capabilities in grossing specimens, not replace humans
-
An accomplishment Jacob is proud of is the impact of the Sentinel in providing confidence to grossing technicians through photographic evidence
-
The future of Vistapath includes expanding the capabilities of the Sentinel to gross a wider range of tissue and leveraging data collected during grossing for downstream processes
-
AI is already transforming pathology, but the data bottleneck is a significant barrier that needs to be addressed for further impact
Links for this episode:
People of Pathology Podcast:
Episode 184: Dr Simone Arvisais-Anhalt And Dr Daniel Qazi: Large Language Models In Pathology: From Chat GPT to Retrieval Augmented Generation
My guests today are Dr Simone Arvisais-Anhalt and Dr Daniel Qazi.
- We discussed the benefits of using LLMs in pathology, including creating outlines, data analysis, and translating reports for patients
- There are also challenges in the use LLMs, such as hallucinations and bias
- Dr. Arvisais-Anhalt and Dr. Qazi described their study on using LLMs in clinical practice
- They were some interesting findings from the study, including different use cases and limitations of the tool
- We talked about future plans to implement retrieval augmented generation for tailored responses in pathology and laboratory medicine
Links for this episode:
What is Retrieval Augmented Generation?
People of Pathology Podcast:
Episode 183: Joseph Mossel – Revolutionizing Pathology with AI: A Conversation with IBEX Co-Founder
Jospeh Mossel co-founded Ibex in 2016. Since its inception, Ibex has remained committed to developing AI applications for clinical diagnostics.
The company achieved its first milestone in 2018 by deploying its first algorithm for prostate cancer. This algorithm not only enhanced diagnostic efficiency but also detected a diagnostic error, demonstrating the value of AI in pathology.
Over the years, IBEX has expanded its offerings to include algorithms for breast and gastric cancers, facing challenges due to the unique characteristics of each tissue type. However, through partnerships with healthcare organizations and pharmaceutical companies, IBEX has continued to innovate and grow.
This conversation covers the history of Ibex and some of their milestones. We conclude with a look toward the future of AI in pathology.
Links for this episode:
People of Pathology Podcast:
Episode 182: Imogen Fitt And Nathan Buchbinder – Emerging Trends In Pathology: From AI to Precision Medicine
My guests today are Imogen Fitt from Signify Research and Nathan Buchbinder from Proscia. We discuss emerging trends in pathology, including:
-
The current technology with the most significant impact in the field of pathology has been artificial intelligence (AI).
-
AI has stirred up imaginations about the future of pathology and has accelerated the timeline for seeing its impact.
-
Return on investment in digital pathology has shifted from being a challenge to becoming an opportunity that drives adoption.
-
Pathologists are not being replaced by AI but rather augmented by it to make their work easier and more efficient.
-
Precision medicine is a key emerging trend in pathology, with a focus on clinical biomarkers, companion diagnostics, and personalized treatment pathways.
-
Telepathology plays a crucial role in improving access to pathology services, especially in underserved areas and remote locations.
-
Collaboration among digital pathology companies is driven by customer demand for interoperability and seamless integration of technologies.
-
The future of pathology technology is likely to focus on precision medicine, clinical biomarkers, companion diagnostics, digital pathology storage, compression algorithms, robotics, and value-based care.
Links for this episode:
People of Pathology Podcast:
Episode 181: Dr Bronwyn Bryant – Redefining Pathology Training With Entrustable Professional Activities
Today my guest is Dr. Bronwyn Bryant, a pathologist and pathology educator.
Dr. Bryant has been involved in the National EPA Working Group, focused on implementing Entrustable Professional Activities (EPAs) in pathology residency programs.
The group conducted a pilot study on EPAs and is now working on developing an electronic tool to facilitate the completion of EPAs in real-time.
Dr. Bryant is passionate about using EPAs to provide more specific and actionable feedback to residents, ultimately improving the learning and assessment experiences. She is also interested in studying the impact of EPAs on resident training.
Dr. Bryant emphasizes the importance of faculty development in using EPAs effectively and believes that this method can lead to a culture shift in pathology education.
Links for this episode:
National pilot of entrustable professional activities in pathology residency training
People of Pathology Podcast:
Episode 180: Exploring Pathology Observerships with Dr Risha Khatri And Dr Abdul Abid
Pathology observerships offer a unique opportunity for medical students and recent graduates to gain firsthand experience and insights into the dynamic field of pathology.
These structured programs provide participants with the chance to observe experienced pathologists at work, learn about various laboratory techniques, and understand the diagnostic process involved in analyzing tissue specimens.
In this episode, we delve into the significance of pathology observerships and how they contribute to the professional development of aspiring pathologists.
Links for this episode:
Match To Path – Guide To Pathology Residency
FREIDA – Search List For Residency Programs
People of Pathology Podcast:
Responses